Previous 10 | Next 10 |
Angion is a recent IPO. It has an ongoing phase 3 trial with near-term data readout. Cash balance is a little low. For further details see: Angion Biomedica: Interesting New IPO With Late Stage Asset Targeting A Novel Indication
Angion is pioneering a new approach to treating acute organ injuries with a pipeline of assets led by ANG-3777, a hepatocyte growth factor (HGF) mimetic. The company has a pivotal trial ongoing aimed at reducing the severity of Delayed Graft Function after kidney transplant. There...
Angion Biomedica (ANGN): Q4 GAAP EPS of -$1.90 misses by $0.60.Revenue of $0.46M (-34.3% Y/Y) misses by $1.44M.As of December 31, 2020, Angion had cash and cash equivalents totaling $34.6 million.Press Release For further details see: Angion Biomedica EPS misses by $0.60, misses on reve...
UNIONDALE, N.Y., March 30, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today pro...
Angion Biomedica (ANGN) has completed enrollment for its ALI-201 study, a Phase 2 trial conducted in Brazil of ANG-3777 for the reduction of severity and progression of acute lung injury in patients with COVID-19 associated pneumonia who are at high risk of progressing to acute respirato...
UNIONDALE, N.Y., March 25, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ: ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today an...
Angion Biomedica (ANGN) announces that its the lead book-running managers in the company's recent public sale of 5.75M shares have agreed to a partial wavier of a lock-up restriction with respect to about 100K shares held by certain employees.The waiver will take effect on March 23, 2021, and...
UNIONDALE, N.Y., March 19, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today ann...
Two IPOs are scheduled to raise $1.3 billion in the week ahead. Street research is expected for 14 companies. Lock-up periods will be expiring for six companies. For further details see: U.S. IPO Week Ahead: Health Insurer Oscar Health Leads A 2 IPO Week
UNIONDALE, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) -- Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, today anno...
News, Short Squeeze, Breakout and More Instantly...
Angion Biomedica Corp. Company Name:
ANGN Stock Symbol:
NASDAQ Market:
NEWTON, Mass., June 01, 2023 (GLOBE NEWSWIRE) -- Angion Biomedia Corp. (NASDAQ: ANGN), a biopharmaceutical company that has focused on the discovery, development, and commercialization of novel small molecule therapeutics to address fibrotic diseases, today announced that it will effect a reverse...
NEW YORK, NY / ACCESSWIRE / April 2, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: INDUS Realty Trust, Inc. (NASDAQ:I...
NEW YORK, NY / ACCESSWIRE / March 19, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Cardiovascular Systems, Inc. (NASDAQ...